

Duchenne Muscular Dystrophy Therapeutics Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/D9632E497961EN.html>

Date: April 2022

Pages: 64

Price: US\$ 3,250.00 (Single User License)

ID: D9632E497961EN

Abstracts

Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.

This report contains market size and forecasts of Duchenne Muscular Dystrophy Therapeutics in Global, including the following market information:

Global Duchenne Muscular Dystrophy Therapeutics Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Duchenne Muscular Dystrophy Therapeutics market was valued at 989.7 million in 2021 and is projected to reach US\$ 5471 million by 2028, at a CAGR of 27.7% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Pain Management Drugs Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Duchenne Muscular Dystrophy Therapeutics include Bristol-Myers Squibb, FibroGen (US), Italfarmaco (Italy), Marathon, NS Pharma (US), PTC Therapeutics (US), Pfizer, ReveraGen BioPharma (US) and Santhera

Pharmaceuticals (Switzerland) and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Duchenne Muscular Dystrophy Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Duchenne Muscular Dystrophy Therapeutics Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Duchenne Muscular Dystrophy Therapeutics Market Segment Percentages, by Type, 2021 (%)

Pain Management Drugs

Corticosteroids

Prednisolone

Prednisone

Deflazacort

Global Duchenne Muscular Dystrophy Therapeutics Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Duchenne Muscular Dystrophy Therapeutics Market Segment Percentages, by Application, 2021 (%)

Hospitals

Clinics

Home Care

Global Duchenne Muscular Dystrophy Therapeutics Market, By Region and Country,
2017-2022, 2023-2028 (\$ Millions)

Global Duchenne Muscular Dystrophy Therapeutics Market Segment Percentages, By
Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Duchenne Muscular Dystrophy Therapeutics revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Duchenne Muscular Dystrophy Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Bristol-Myers Squibb

FibroGen (US)

Italfarmaco (Italy)

Marathon

NS Pharma (US)

PTC Therapeutics (US)

Pfizer

ReveraGen BioPharma (US)

Santhera Pharmaceuticals (Switzerland)

Sarepta Therapeutics (US)

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Duchenne Muscular Dystrophy Therapeutics Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Duchenne Muscular Dystrophy Therapeutics Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL DUCHENNE MUSCULAR DYSTROPHY THERAPEUTICS OVERALL MARKET SIZE

- 2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size: 2021 VS 2028
- 2.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Duchenne Muscular Dystrophy Therapeutics Players in Global Market
- 3.2 Top Global Duchenne Muscular Dystrophy Therapeutics Companies Ranked by Revenue
- 3.3 Global Duchenne Muscular Dystrophy Therapeutics Revenue by Companies
- 3.4 Top 3 and Top 5 Duchenne Muscular Dystrophy Therapeutics Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Duchenne Muscular Dystrophy Therapeutics Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Duchenne Muscular Dystrophy Therapeutics Players in Global Market
 - 3.6.1 List of Global Tier 1 Duchenne Muscular Dystrophy Therapeutics Companies

3.6.2 List of Global Tier 2 and Tier 3 Duchenne Muscular Dystrophy Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Duchenne Muscular Dystrophy Therapeutics Market Size Markets, 2021 & 2028

4.1.2 Pain Management Drugs

4.1.3 Corticosteroids

4.1.4 Prednisolone

4.1.5 Prednisone

4.1.6 Deflazacort

4.2 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue & Forecasts

4.2.1 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2022

4.2.2 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2023-2028

4.2.3 By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Duchenne Muscular Dystrophy Therapeutics Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Clinics

5.1.4 Home Care

5.2 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue & Forecasts

5.2.1 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2022

5.2.2 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2023-2028

5.2.3 By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Duchenne Muscular Dystrophy Therapeutics Market Size, 2021 & 2028

6.2 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue & Forecasts

6.2.1 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2022

6.2.2 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2023-2028

6.2.3 By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028

6.3.2 US Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.3.3 Canada Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.3.4 Mexico Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028

6.4.2 Germany Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.4.3 France Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.4.4 U.K. Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.4.5 Italy Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.4.6 Russia Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.4.7 Nordic Countries Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.4.8 Benelux Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028

6.5.2 China Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.5.3 Japan Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.5.4 South Korea Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.5.5 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.5.6 India Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028

6.6.2 Brazil Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.6.3 Argentina Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028

6.7.2 Turkey Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.7.3 Israel Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.7.4 Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

6.7.5 UAE Duchenne Muscular Dystrophy Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Bristol-Myers Squibb

7.1.1 Bristol-Myers Squibb Corporate Summary

7.1.2 Bristol-Myers Squibb Business Overview

7.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Major Product Offerings

7.1.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)

7.1.5 Bristol-Myers Squibb Key News

7.2 FibroGen (US)

7.2.1 FibroGen (US) Corporate Summary

7.2.2 FibroGen (US) Business Overview

7.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings

7.2.4 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)

7.2.5 FibroGen (US) Key News

7.3 Italfarmaco (Italy)

7.3.1 Italfarmaco (Italy) Corporate Summary

7.3.2 Italfarmaco (Italy) Business Overview

7.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings

7.3.4 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)

- 7.3.5 Italfarmaco (Italy) Key News
- 7.4 Marathon
 - 7.4.1 Marathon Corporate Summary
 - 7.4.2 Marathon Business Overview
 - 7.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
 - 7.4.4 Marathon Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
 - 7.4.5 Marathon Key News
- 7.5 NS Pharma (US)
 - 7.5.1 NS Pharma (US) Corporate Summary
 - 7.5.2 NS Pharma (US) Business Overview
 - 7.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
 - 7.5.4 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
 - 7.5.5 NS Pharma (US) Key News
- 7.6 PTC Therapeutics (US)
 - 7.6.1 PTC Therapeutics (US) Corporate Summary
 - 7.6.2 PTC Therapeutics (US) Business Overview
 - 7.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
 - 7.6.4 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
 - 7.6.5 PTC Therapeutics (US) Key News
- 7.7 Pfizer
 - 7.7.1 Pfizer Corporate Summary
 - 7.7.2 Pfizer Business Overview
 - 7.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
 - 7.7.4 Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
 - 7.7.5 Pfizer Key News
- 7.8 ReveraGen BioPharma (US)
 - 7.8.1 ReveraGen BioPharma (US) Corporate Summary
 - 7.8.2 ReveraGen BioPharma (US) Business Overview
 - 7.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings
 - 7.8.4 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)
 - 7.8.5 ReveraGen BioPharma (US) Key News

7.9 Santhera Pharmaceuticals (Switzerland)

7.9.1 Santhera Pharmaceuticals (Switzerland) Corporate Summary

7.9.2 Santhera Pharmaceuticals (Switzerland) Business Overview

7.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings

7.9.4 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)

7.9.5 Santhera Pharmaceuticals (Switzerland) Key News

7.10 Sarepta Therapeutics (US)

7.10.1 Sarepta Therapeutics (US) Corporate Summary

7.10.2 Sarepta Therapeutics (US) Business Overview

7.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Major Product Offerings

7.10.4 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue in Global Market (2017-2022)

7.10.5 Sarepta Therapeutics (US) Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Duchenne Muscular Dystrophy Therapeutics Market Opportunities & Trends in Global Market

Table 2. Duchenne Muscular Dystrophy Therapeutics Market Drivers in Global Market

Table 3. Duchenne Muscular Dystrophy Therapeutics Market Restraints in Global Market

Table 4. Key Players of Duchenne Muscular Dystrophy Therapeutics in Global Market

Table 5. Top Duchenne Muscular Dystrophy Therapeutics Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Companies, 2017-2022

Table 8. Global Companies Duchenne Muscular Dystrophy Therapeutics Product Type

Table 9. List of Global Tier 1 Duchenne Muscular Dystrophy Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Duchenne Muscular Dystrophy Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Duchenne Muscular Dystrophy Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Duchenne Muscular Dystrophy Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Duchenne Muscular Dystrophy Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Duchenne Muscular Dystrophy Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 30. Bristol-Myers Squibb Corporate Summary

Table 31. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product Offerings

Table 32. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 33. FibroGen (US) Corporate Summary

Table 34. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings

Table 35. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 36. Italfarmaco (Italy) Corporate Summary

Table 37. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product Offerings

Table 38. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 39. Marathon Corporate Summary

Table 40. Marathon Duchenne Muscular Dystrophy Therapeutics Product Offerings

Table 41. Marathon Duchenne Muscular Dystrophy Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 42. NS Pharma (US) Corporate Summary

Table 43. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings

Table 44. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 45. PTC Therapeutics (US) Corporate Summary

Table 46. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings

Table 47. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 48. Pfizer Corporate Summary

Table 49. Pfizer Duchenne Muscular Dystrophy Therapeutics Product Offerings

Table 50. Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 51. ReveraGen BioPharma (US) Corporate Summary

Table 52. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings

Table 53. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 54. Santhera Pharmaceuticals (Switzerland) Corporate Summary

Table 55. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product Offerings

Table 56. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 57. Sarepta Therapeutics (US) Corporate Summary

Table 58. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product Offerings

Table 59. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Duchenne Muscular Dystrophy Therapeutics Segment by Type in 2021
- Figure 2. Duchenne Muscular Dystrophy Therapeutics Segment by Application in 2021
- Figure 3. Global Duchenne Muscular Dystrophy Therapeutics Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Duchenne Muscular Dystrophy Therapeutics Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Duchenne Muscular Dystrophy Therapeutics Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Duchenne Muscular Dystrophy Therapeutics Revenue in 2021
- Figure 8. By Type - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
- Figure 12. US Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028
- Figure 16. Germany Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn),

2017-2028

Figure 21. Nordic Countries Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028

Figure 24. China Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 28. India Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028

Figure 30. Brazil Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Revenue Market Share, 2017-2028

Figure 33. Turkey Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Duchenne Muscular Dystrophy Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 37. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Marathon Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Pfizer Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Duchenne Muscular Dystrophy Therapeutics Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/D9632E497961EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D9632E497961EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

